The assessment of CTnI levels indicated that DOX administration significantly increased CTnI levels (0.071 ± 0.022 ng/mL) compared to the control group (0.019 ± 0.007 ng/mL), confirming that DOX therapy induces pathological remodeling of cardiomyopathy. Here, TNNI3 is linked to cardiomyopathy.